Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Most muscle pain from rosuvastatin is mild, reversible myalgia that fades after the dose is adjusted or stopped, but rare cases signal rhabdomyolysis, a serious breakdown of muscle tissue that can injure the kidneys, and warning signs include severe or widespread muscle pain, weakness, dark cola-colored urine, fever, and nausea. Permanent damage is uncommon and usually linked to delayed treatment, high doses, interacting medications, kidney or thyroid problems, or an immune-mediated necrotizing myopathy that can persist after the statin is discontinued. Several factors influence how worried you should be, including timing, severity, and lab results such as creatine kinase, so see below to understand more before deciding whether your symptoms are routine or urgent.
Because ordinary statin soreness and early rhabdomyolysis can feel similar at first, it helps to sort out your specific pattern of symptoms rather than waiting to see what happens. Take a free, instant, online symptom check to better understand what may be causing your muscle pain and what steps to take next.
Last reviewed for medical accuracy: 09/12/2026
Can rosuvastatin muscle pain be a sign of rhabdomyolysis or permanent damage?
Rosuvastatin is a widely prescribed statin medication used to lower cholesterol and reduce cardiovascular risk. As with all medications, it carries potential side effects. One concern patients often have is muscle pain—could this signal a serious condition like rhabdomyolysis or permanent muscle damage? This guide will help you understand the risks, recognize warning signs, and know when to seek medical care.
Rosuvastatin belongs to the statin class of drugs. Its primary action is to inhibit HMG-CoA reductase, an enzyme in the liver responsible for producing cholesterol. By doing so, rosuvastatin:
These benefits generally outweigh risks for patients with elevated cholesterol or pre-existing heart disease. Yet, awareness of possible rosuvastatin side effects—especially muscle-related ones—is crucial.
Most people tolerate rosuvastatin well. Common, mild side effects include:
These effects often resolve within a few weeks or after a dosage adjustment. However, persistent or severe muscle pain warrants closer attention.
Muscle-related complaints range from mild soreness to life-threatening conditions:
Statin-associated rhabdomyolysis is extremely rare—estimates range from 0.01% to 0.1% of statin users. However, because of its potential severity, patients and clinicians remain vigilant.
Early detection of rhabdomyolysis can prevent complications. Key warning signs include:
If you experience any combination of these symptoms, it’s essential to act promptly.
Permanent muscle damage from rosuvastatin is exceedingly rare. In most cases, muscle cells regenerate once the offending agent is removed and appropriate treatment is given. However, prolonged untreated rhabdomyolysis can lead to:
Timely intervention dramatically reduces the risk of lasting harm.
Certain factors increase the likelihood of statin-associated muscle complications:
Discuss your full medical history and medication list with your doctor before starting rosuvastatin.
To minimize the risk of rosuvastatin muscle pain progressing:
Even if you’re unsure whether your muscle symptoms are serious, it’s better to err on the side of caution. Consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help assess your risk. If the results are concerning, or if you have any of the rhabdomyolysis warning signs listed above, contact your healthcare provider or go to the nearest emergency department.
Remember, the cardiovascular protection afforded by rosuvastatin often far outweighs its risks for most patients. Millions of people take statins safely every day. By maintaining open communication with your healthcare team and reporting side effects early, you can enjoy the heart-protective benefits while keeping muscle complications at bay.
Staying informed and proactive ensures you get maximum benefit from rosuvastatin while minimizing the chance of serious muscle injury. If in doubt, don’t hesitate to reach out to your healthcare provider.
(References)
* Shepherd J, Hunninghake DB, Stein EA, Kastelein JJ, Harris S, Pears J, Hutchinson HG. Safety of rosuvastatin. Am J Cardiol. 2004 Oct 1;94(7):882-8. doi: 10.1016/j.amjcard.2004.06.049. PMID: 15464670.
* Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. doi: 10.1111/j.1472-8206.2004.00299.x. PMID: 15660968.
* Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. PMID: 18997196.
* Bajaj T, Patel P, Giwa AO. Rosuvastatin. 2026 Jan. PMID: 30969705.
* Balasubramanian R, Maideen NMP. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview. Curr Drug Metab. 2021;22(5):328-341. doi: 10.2174/1389200222666210114122729. PMID: 33459228.
* Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.
* Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022 Sep 10;400(10355):832-845. doi: 10.1016/S0140-6736(22)01545-8. Epub 2022 Aug 29. PMID: 36049498; PMCID: PMC7613583.
* Kammoun R, Charfi O, Lakhoua G, Zaiem A, Daghfous R, Kastalli S, Aouinti I, Aidli SE. Statin Associated Muscular Adverse Effects. Curr Drug Saf. 2024;19(1):114-116. doi: 10.2174/1574886318666230227143627. PMID: 36847228.
* Montastruc JL. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins. Br J Clin Pharmacol. 2023 Aug;89(8):2636-2638. doi: 10.1111/bcp.15757. Epub 2023 May 8. PMID: 37186323.
* Li W, Wang D, Lin C, Cai T, Zhao M, Liang L, Zhao X, He X, Liang X, Zheng J. A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases. Cardiovasc Ther. 2025;2025:6684099. doi: 10.1155/cdr/6684099. Epub 2025 Jun 10. PMID: 40529509; PMCID: PMC12173554.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.